Longevity One » Post-mitotic cardiomyocyte senescence redefines cardiac ageing
Contributor+

Post-mitotic cardiomyocyte senescence redefines cardiac ageing

August 4, 2026
3 min read
Email
Facebook
X
LinkedIn
Print
On this page
  1. Access options
  2. Additional access options:
  3. Subjects
  4. References
  5. Author information
  6. Authors and Affiliations
  7. Corresponding author
  8. Ethics declarations
  9. Competing interests
  10. Rights and permissions
  11. About this article
  12. Cite this article
  • Journal Club
  • Published:

Cardiac ageing

Nature Reviews Cardiology (2026) Cite this article

For decades, cellular senescence was regarded as a hallmark of proliferative cells. First described as an irreversible cell-cycle arrest that limits the propagation of damaged cells, senescence was widely viewed as a potent tumour-suppressive mechanism. Senescent cells also emerged as key drivers of chronic diseases, which fuelled intense efforts to develop senolytic drugs (which selectively eliminate senescent cells) and senomorphic therapies (which modulate the senescence-associated secretory phenotype (SASP)) for age-related disorders. However, because cardiomyocytes are post-mitotic cells, they were largely considered exempt from senescence biology. Therefore, whether terminally differentiated cells could also undergo senescence remained largely unexplored.

This paradigm shifted with the 2019 landmark study by Anderson and colleagues, who showed that post-mitotic cardiomyocytes progressively acquire a senescent phenotype with age. Rather than defining senescence by proliferative arrest, the investigators established that persistent cellular stress triggers a senescence program even in differentiated cells. By demonstrating that senescence can develop independently of cell-cycle arrest, the investigators expanded the concept of cellular senescence beyond proliferative tissues and redefined cardiomyocytes as active drivers of cardiac ageing. Most importantly, the study established that senescent cardiomyocytes are not merely passive markers of ageing. Instead, these cells actively remodel the myocardial microenvironment through a non-canonical SASP enriched in pro-fibrotic and pro-hypertrophic mediators. Despite representing only a small fraction of the cardiomyocyte population, senescent cardiomyocytes were shown to promote myocardial fibrosis and cardiomyocyte hypertrophy in mice, suggesting that a limited number of dysfunctional cells is sufficient to orchestrate tissue-wide remodelling. This concept fundamentally changed how researchers viewed the ageing myocardium: not as a tissue that simply accumulates damaged cardiomyocytes, but as one in which stressed cardiomyocytes actively instruct pathological remodelling.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

$32.99 / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

$189.00 per year

only $15.75 per issue

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Subjects

References

Author information

Authors and Affiliations

  1. University of Toulouse, Inserm, I2MC, Toulouse, France

    Ilias Simon & Yohan Santin

  2. IHU HealthAge, Toulouse, France

    Yohan Santin

Authors

  1. Ilias Simon
  2. Yohan Santin

Corresponding author

Correspondence to Yohan Santin.

Ethics declarations

Competing interests

The authors declare no competing interests.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Simon, I., Santin, Y. Post-mitotic cardiomyocyte senescence redefines cardiac ageing. Nat Rev Cardiol (2026). https://doi.org/10.1038/s41569-026-01332-5

Download citation

  • Published:

  • Version of record:

  • DOI: https://doi.org/10.1038/s41569-026-01332-5

More from LongevityOne